Glenmark Life Sciences Limited (GLS.BO)

Glenmark Life Sciences Limited engages in the development, manufacture, and supply of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. It offers Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, and Cilostazol for the treatment of cardiovascular disease; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for the treatment of central nervous system disease; Remogliflozin, Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin for the treatment of diabetes; Etoricoxib, Lornoxicam, Zolmitriptan, and Frovatriptan for pain management; and Olaparib, Palbociclib, Enzalutamide, and Ruxolitinib for oncology treatment, as well as Atovaquone, an anti-parasitic and Adapalene, a dermatology product. The company also provides contract development and manufacturing services to a range of multinational pharmaceutical and specialty pharmaceutical companies. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited operates as a subsidiary of Glenmark Pharmaceuticals Limited.